- Title: ClinGen Variant Curation Interface: A Variant Classification Platform for the Application
   of Evidence Criteria from ACMG/AMP Guidelines
- 3

4 Short Title: ClinGen Variant Curation Interface (VCI)

5

Authors: Christine G. Preston<sup>1#</sup>, Matt W. Wright<sup>1#</sup>, Rao Madhavrao<sup>1</sup>, Steven M. Harrison<sup>2</sup>, 6 Jennifer L. Goldstein<sup>3</sup>, Xi Luo<sup>4</sup>, Hannah Wand<sup>5</sup>, Bryan Wulf<sup>1</sup>, Gloria Cheung<sup>1</sup>, Mark E. 7 Mandell<sup>1</sup>, Howard Tong<sup>1</sup>, Shaung Cheng<sup>1</sup>, Michael A. Iacocca<sup>1</sup>, Arturo Lopez Pineda<sup>6</sup>, Alice B. 8 Popejoy<sup>6</sup>, Karen Dalton<sup>7</sup>, Jimmy Zhen<sup>7</sup>, Selina S. Dwight<sup>8</sup>, Lawrence Babb<sup>2</sup>, Marina DiStefano<sup>2</sup>, 9 Julianne M. O'Daniel<sup>3</sup>, Kristy Lee<sup>3</sup>, Erin R. Riggs<sup>9</sup>, Diane B. Zastrow<sup>10</sup>, Jessica L. Mester<sup>11</sup>, 10 Deborah I. Ritter<sup>4</sup>, Ronak Y. Patel<sup>12</sup>, Sai Lakshmi Subramanian<sup>12</sup>, Aleks Milosavljevic<sup>12</sup>, 11 Jonathan S. Berg<sup>3</sup>, Heidi L. Rehm<sup>2,13</sup>, Sharon E. Plon<sup>4,12</sup>, J. Michael Cherry<sup>14</sup>, Carlos D. 12 Bustamante<sup>6,14</sup>, Helio A. Costa<sup>1,6</sup>\*, on behalf of the Clinical Genome (ClinGen) Resource 13 14

# 15 Affiliations:

<sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 USA

<sup>17</sup> <sup>2</sup>Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142

18 USA

<sup>3</sup>Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 USA

<sup>4</sup>Department of Pediatrics/Hematology-Oncology, Baylor College of Medicine, Houston, TX
77030 USA

<sup>5</sup>Center for Inherited Cardiovascular Disease, Stanford Health Care, Stanford, CA 94305 USA

- <sup>6</sup>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA
- 24 94305 USA
- <sup>7</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 USA
- 26 <sup>8</sup>Grace Science LLC, Menlo Park, CA 94025 USA
- 27 <sup>9</sup>Autism & Developmental Medicine Institute, Geisinger Health System, Lewisburg, PA 17837
- 28 USA
- 29 <sup>10</sup>Sutter Health, Mountain View, CA 94040 USA
- 30 <sup>11</sup>GeneDx Inc., Gaithersburg, MD 20877 USA
- 31 <sup>12</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

32 77030 USA

- 33 <sup>13</sup>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
- <sup>14</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305 USA
- 35 #These authors contributed equally to this work
- 36 \*Correspondence to: Helio A. Costa, Ph.D. (H.A.C.), Stanford University, Department of
- Pathology, 300 Pasteur Drive, MSOB x313, Stanford, CA 94305. Email: hcosta@stanford.edu
- 39 Keywords: Variant Curation; Precision Medicine; Medical Genetics; Clinical Genome Resource
- 40 Consortium
- 41
- 42 **Tables**: 1

43

44 **Figures**: 6

46 Sources of support: This research was funded by grants from the National Human Genome
47 Research Institute (NHGRI) of the National Institutes of Health (U41HG009649,
48 U01HG007436, U41HG006834, U01HG007434, U41HG009650).

49

50 Disclosure: S.E.P. is a member of the Baylor Genetics Scientific Advisory Panel. A.M. is an 51 employee of Baylor College of Medicine (BCM) and performs integration consulting services for 52 BCM-developed software including Genboree through IP Genesis Inc. C.D.B. is on the scientific advisory boards (SAB) of AncestryDNA, Arc Bio LLC, Etalon DX, Liberty Biosecurity, and 53 Personalis. C.D.B. is on the board of EdenRoc Sciences LLC. C.D.B. is also a founder and SAB 54 55 chair of ARCBio. J.L.M. is an employee of GeneDx/BioReference Laboratories, Inc./OPKO 56 Health and has a salary as the only disclosure. None of these entities played a role in the design, 57 execution, interpretation, or presentation of this study.

59 Abstract:

60

Background: Identification of clinically significant genetic alterations involved in human 61 62 disease has been dramatically accelerated by developments in next-generation sequencing 63 technologies. However, the infrastructure and accessible comprehensive curation tools necessary for analyzing an individual patient genome and interpreting genetic variants to inform healthcare 64 65 management have been lacking. Results: Here we present the ClinGen Variant Curation Interface (VCI), a global open-source variant classification platform for supporting the 66 application of evidence criteria and classification of variants based on the ACMG/AMP variant 67 classification guidelines. The VCI is among a suite of tools developed by the NIH-funded 68 69 Clinical Genome Resource (ClinGen) Consortium, and supports an FDA-recognized human 70 variant curation process. Essential to this is the ability to enable collaboration and peer review 71 across ClinGen Expert Panels supporting users in comprehensively identifying, annotating, and 72 sharing relevant evidence while making variant pathogenicity assertions. To facilitate evidence-73 based improvements in human variant classification, the VCI is publicly available to the 74 genomics community and is available at https://curation.clinicalgenome.org. Navigation 75 workflows support users providing guidance to comprehensively apply the ACMG/AMP 76 evidence criteria and document provenance for asserting variant classifications. Conclusion: The 77 VCI offers a central platform for clinical variant classification that fills a gap in the learning healthcare system, and facilitates widespread adoption of standards for clinical curation. 78

## 80 Introduction:

81

82 The application of genomics to precision medicine holds great promise for the implementation of 83 tailored diagnostics, optimized patient care management, and personalized therapies in 84 healthcare. The past decade has seen the development of technological and computational 85 innovations to bring both DNA-sequencing methodologies and bioinformatic algorithms into 86 routine standard-of-care for diagnostic medical genomics. While there has been broad consensus 87 in terms of bioinformatic best practices, quality control metrics, and community adoption of variant calling and classification standards, substantial variability remains among variant 88 curation tools and data sharing by health care providers, clinical diagnostic laboratories, and 89 90 researchers.

91 Clinical interpretation of genomic sequencing data requires both the standardization of variant 92 classification guidelines, as well as consistency in the workflow and evidence considered when 93 determining the relationship between a variant and a disease phenotype. Since the 2015 release of the American College of Medical Genetics and Genomics / Association for Molecular 94 Pathology (ACMG/AMP) guidelines<sup>1</sup>, the genomics community has substantially adopted<sup>2</sup> the 95 96 standards outlined by Richards et al. and the guidance provided by the Clinical Genome Resource (ClinGen) Consortium<sup>3</sup> to aid in further refining and standardizing the evaluation of 97 sequence variant pathogenicity  $4^{-16}$ . 98

99 While the creation of these variant classification guidelines and standards is a central objective, 100 there is also a significant unmet need for computational infrastructure and curation software to 101 guide biocurators through these complex curation workflows. Here we present the ClinGen 102 Variant Curation Interface (VCI), which is a comprehensive variant classification platform designed to support both individual and group classification in accordance with the ACMG/AMP guidelines. The VCI is intended to be a publicly available variant curation tool which programmatically guides users through a standard process for variant evidence classification and application of ACMG/AMP guidelines in a controlled workflow to enforce rigor and quality in variant classification (**Figure 1**).

108

## 109 **Implementation**:

110

The VCI curation platform has been developed to facilitate the FDA-recognized ClinGen variant classification process, support transparent evidence review, and provide timely dissemination to the genomics community. Users can curate individually or communally in groups known as affiliations. The VCI programmatically displays relevant data types from external sources (**Table 1**), and displays evidence identified by other VCI users in an organized user interface enabling an environment to document ACMP/AMP criteria codes.

117

118 The core elements of the VCI data model are shown in **Figure 2**. The full data model is stored in 119 Javascript Object Notation (JSON) format with references to data elements. The data model is 120 centered upon a variant classification, with attributes consisting of data and context related to 121 asserting the variant's pathogenicity. The classification model is based on the combined variant, 122 disease, and mode of inheritance data models. Each variant is evaluated by biocurators against 123 specific evidence types which are reflected in the VCI's data models, (e.g. population data, 124 experimental data, computational data), as well as literature-based evidence which can be 125 manually added by a biocurator and related to any of the other evidence types. Biocuratorselected evaluations of the evidence criteria provide a computed variant pathogenicity, which can
be manually overridden by biocurators based on expert opinion consistent with the ACMG/AMP
guidelines.

129

130 The classification model is designed to support the ClinGen workflow of variant curation, which 131 is an iterative and manual process, with biocurators making criteria evaluations, and expert 132 panels considering and approving final classifications. This is modeled in the platform in two 133 ways, first each variant classification has a status attribute that indicates the most recent status of 134 the classification, ('In-progress', 'Provisional', 'Approved', 'Published', 'New-Provisional'). 135 Secondly, the classification model only stores references to its related models (e.g. variant, 136 disease, evidence, evidence criteria), which also store the most recent information. When a 137 classification has a status of 'Provisional', 'Approved' or 'Published', the snapshot model is used 138 to store an instance (point in time) containing all of the related data. This allows changes to the 139 related data to be identified, while previous data, which may have been used to make a criteria 140 evaluation, are still preserved in the snapshot. Snapshots published to ERepo and ClinVar 141 undergo a transformation to SEPIO (http://dataexchange.clinicalgenome.org/interpretation/index.html).

142

The VCI is accessed through a web browser where users can perform curation activities including review of imported evidence, entry of evidence gathered from published and unpublished sources, ACMG/AMP criteria application, pathogenicity evaluation, and classification review and approval. The classified variants from ClinGen-approved Variant Curation Expert Panels (VCEPs) are then shared with the ClinGen Evidence Repository (ERepo; 148https://erepo.clinicalgenome.org/)andtheClinVardatabase149(https://www.ncbi.nlm.nih.gov/clinvar/)to enable peer review and public access.

150

The software for the VCI is freely and openly available via publicly accessible web pages and a publicly available GitHub repository (<u>https://github.com/ClinGen/clincoded/</u>). The VCI website (<u>https://curation.clinicalgenome.org</u>) is developed as a common interface for both the VCI and the related Gene Curation Interface (GCI), using the same platform and sharing components such as a user database and classification data. User access to the VCI and GCI is available by authenticated login. Login permissions are required in order to document the provenance of evidence added to the interfaces.

158

159 Users access the VCI web application via the browser and execute the workflow tasks needed to 160 perform variant curation. The current deployment, VCI v2.0, utilizes cloud-based web 161 development best practices and a "serverless architecture", which is a cloud development 162 approach where all application resource management and scaling needs are automatically 163 determined and handled by the cloud services. All of the components essential for the application including authentication, gateways to receive and respond to browser requests, microservices, 164 165 and storage are provided by Amazon Web Services (AWS). This scalable and robust architecture 166 is based on several AWS serverless components shown in **Figure 3**, the role of key components 167 are further described here. The API Gateway handles tens of thousands of requests per second 168 and provides automatic schema validation of data, ensuring data integrity in the VCI. Lambda 169 spawns microservices to store or retrieve data, managing and scaling the computing resources 170 required by the VCI. DynamoDB is a flexible, document-based database that provides constant

171 load-independent performance, supporting the VCI in long-term goals of scaling to large 172 numbers of variant classifications and providing bulk variant curation support, while S3 stores 173 the large VCI database. Additionally, Cognito is used for user management, and Amplify for 174 web content integration with backend microservices. The user interfaces are created using 175 standard JavaScript programming (ReactJS) and they obtain information from the database via 176 an Application Programming Interface (API) using a standard JSON format. For comparison, 177 this continuous integration and deployment provides greater reliability and cost-savings relative 178 to the initial deployment of the VCI v1.0 built following a classical three-tier architecture with a 179 web-frontend component (ReactJS), backend business logic layer (Python and Pyramid), a split 180 persistence layer containing the state and metadata database (PostgreSQL) and search indexes 181 (AWS Elasticsearch).

182

Services components include an external resource manager, which is responsible for obtaining
data from external sources (**Table 1**) that feed into the variant, gene, disease, population,
predictive, functional and gene data models.

186

Finally, ClinGen provides supplemental resources for VCI users including general information
about biocuration, summary videos outlining the concepts and methods behind biocuration, and
links to biocuration resources such as ClinGen's documented standard operating procedures
(https://clinicalgenome.org/curation-activities/variant-pathogenicity/).

191

192 <u>Development Process</u>

The VCI software and product development teams worked alongside the ClinGen Variant Curation Interface Task Team to develop the initial platform. This product was designed through a user engagement process and VCI v1.0 was launched for use in September 2016, with new features developed and released monthly. The completely re-architected and updated VCI v2.0 platform was launched in December 2020, and is the current production version.

199 VCI development continues to evolve with the input of core members of the ClinGen variant 200 curation community that meet twice per month with the VCI development team. This group 201 includes members of the ClinGen Sequence Variant Interpretation (SVI) Working Group, which provides guidance on how to interpret, refine, and standardize the ACMG/AMP guidelines<sup>5-</sup> 202 <sup>7,11,16</sup>, and members of ClinGen's Variant Curation Expert Panels (VCEPs). Additional guidance 203 204 for VCI development comes from the ClinGen Data Access, Protection and Confidentiality 205 (DAPC) Working Group, which reviews tools and data practices in the ClinGen curation 206 ecosystem to ensure that software development efforts are informed by updated data sharing 207 policies. Detailed best practice recommendations for biocurator use of the VCI and associated resources for variant classification are provided in the ClinGen Variant Curation Standard 208 209 Operating Procedure.

## 210 *Variant Identification and Evidence*

It is possible to define a variant in several different ways. This promiscuity arises as a result of the availability of multiple transcripts and genomic reference sequences and various ways to describe insertion/deletions. As a result, unambiguous identification of variants is critical to the downstream usability of the curated data. The VCI identifies a variant by either a ClinVar Variation ID<sup>17</sup> or a ClinGen Allele Registry ID<sup>18</sup>. The variant is then associated with a Mondo Disease Ontology<sup>18</sup> term and a Human Phenotype Ontology<sup>19</sup> mode of inheritance term by the biocurator or VCEP. Recognizing that a variant can be curated for more than one potential disease, each user is restricted to one variant classification record per variant. Within the interfaces each variant is titled based on a hierarchy of naming conventions, preferentially using a title based on the MANE Select<sup>20</sup> transcript when available (**Figure 4A**).

221 The VCI aggregates and displays multiple types of evidence about a variant, separated into six 222 tabs structured by data type, providing a rich and structured evidence gathering experience to 223 biocurators, while supporting variant classification in accordance with the ACMG/AMP 224 guidelines. This promotes consistency in terms of the evidence evaluated, application of the 225 ACMG/AMP criteria, and pathogenicity calculations. In keeping with the ClinGen goal to support appropriate community data sharing, all evidence added by users is viewable by any 226 227 other VCI user. While all evidence is viewable by all users, a user's evidence evaluations and 228 pathogenicity calculations remain private until the classification record has been finalized (set to 229 'Approved' status), at which point other users can view, but not edit the final classification in the 230 VCI.

231

#### 232 <u>Automated Evidence</u>

233

The VCI programmatically retrieves and displays many different types of evidence for each variant (**Table 1**). This includes the many possible variant nomenclatures on different transcripts and human genome builds, population frequency data, *in silico* prediction scores, conservation data, gene and protein resources, and all classifications and submissions for the variant currently present in ClinVar or the VCI. When evidence is unavailable for direct display via API, dynamic links to external information sources are embedded within the relevant evidence tab. Relevant
external information sources are identified in conjunction with core members of the ClinGen
variant curation community described above.

242

## 243 <u>Manually-Curated Evidence and Structured Data Capture</u>

244

245 Users can manually add information relevant to the variant being classified from published 246 articles for any evidence type into the relevant sections in the VCI. Additionally, structured data 247 capture is supported for published functional data, and for published and unpublished case and 248 segregation evidence. Such structured data inputs ensure curation consistency, as they organize 249 and accurately define the information so that it can easily be retrieved, facilitate searching of the 250 captured data, and enable downstream data processing applications such as data mining and 251 machine learning. Two examples of structured data capture within the VCI are outlined below 252 (Functional Data Capture and Case Level Data Capture).

253

## 254 *Functional Data Capture*

255

The ACMG/AMP guidelines require the assessment of well established *in vivo* or *in vitro* functional studies showing 'no damaging effect' (BS3) or 'supportive of damaging effect' (PS3) on protein function or splicing. We have developed a structured framework with the narrative of 1) method, 2) material, and 3) effect (with or without a quantifier), using standardized terminology from ontologies, in order for users to define the functional data they have derived from published articles in a consistent and reproducible way. We provide users with a

262 standardized template for capturing these structured data which they can then submit to 263 ClinGen's Functional Data Repository (FDRepo [https://ldh.genome.network/fdr/ui/]); subsequently, these granular functional data for each variant are viewable in the 'Experimental' 264 265 tab in the VCI. Future enhancements will include updating the structured narrative and data fields in accordance with new standards<sup>7</sup> and augmenting capacity for bulk annotations to be 266 267 imported from literature annotations or databases of functional evidence including the increasing availability of data from multiplex assays of variant effect<sup>21,22</sup>. 268

269

#### 270 <u>Case Level Data Capture</u>

271

272 Case level and segregation level data are critical to pathogenicity evaluations using the 273 ACMG/AMP guidelines. However, individual case observations have the potential to be linked 274 to individual patient identities if enough ancillary information is also included about the case. It 275 is for this reason that the case-segregation tab of the VCI prompts users to remember the Terms 276 of Use for this tool, which include prohibitions on entering protected health information (PHI) or 277 other sensitive information that could possibly identify an individual data subject, and entering 278 only the minimum necessary information to resolve a particular case. In order to further protect 279 data subjects from the possibility of re-identification (which is also strictly prohibited for users of 280 the VCI as stated in the Terms of Use), individual case-level data are not made publicly available 281 through ClinGen tools except in aggregate. When entering in case observations or pedigree 282 segregation evidence, users are directed to a form that has separate fields to capture each distinct 283 case-level observation or co-segregation events. Then, individual counts for each distinct data type are summed together and analyzed in aggregate along with the same information from otherevidence sources (Figure 5B).

286

287 <u>Curation Workflow</u>

288

289 ClinGen variant curation through the VCI enables use of the nomenclature, criteria codes and 290 rules defined in the joint 2015 ACMG/AMP guidelines on variant classification. Embedded 291 flexibility is designed to allow biocurators to incorporate modifications and additional guidance 292 produced by ClinGen's Sequence Variant Interpretation WG as well as disease specifications 293 from ClinGen VCEPs following the FDA-recognized validation process. To further aid this 294 process, the VCI allows groups of users to curate variants as a single entity, known as an 'affiliation'. VCI affiliations are often ClinGen Variant Curation Expert Panels (VCEPs)<sup>23,24</sup>; 295 296 however, any group of users who wish to curate variants together (e.g. a clinical or research 297 laboratory) may form an affiliation. Once a VCI user initiates a classification it belongs to that 298 individual or affiliation, and can only be edited by them.

299

The ACMG/AMP guidelines provide a set of criteria to be considered when classifying a variant. The VCI is designed to help users evaluate the applicability of these criteria in an efficient and structured way (**Figure 1**). The VCI groups criteria by evidence types; displaying both the relevant criteria and any related evidence. These groups are: 1) Population (known variant allele frequencies), 2) Variant Type (predicted impact of the variant on the gene product), 3) Experimental (functional assay data), and 4) Case/Segregation (relevant observations of the variant). The VCI also groups together gene-focused resource links, and basic information, displaying ClinVar and VCI curations for the variant as well as the molecular consequence of the
variant on all known transcripts (Figure 4C and Table 1).

309

310 For each ACMG/AMP criteria, users are provided a description of the guideline in the VCI. The 311 user is able to view, add and evaluate the relevant evidence, and then set their criteria evaluation 312 and write an explanation. As some criteria are applicable at different pathogenicity strengths, 313 users can choose the appropriate strength from a pulldown list containing only the appropriate 314 strength options for that criterion. For instance, the available options provided for evaluating PP1 315 are: Not Evaluated, Met, Not Met, PP1 Moderate, and PP1 Strong. As a user saves their 316 evaluations, a criteria bar (Figure 4B) in the header of the interface keeps track of their progress 317 by indicating which criteria have been 'Met' (solid color background with white criteria code), 318 'Not Met' (grey background with colored criteria code), or remain 'Not Evaluated' (white 319 background with colored criteria code). If a user scrolls over individual criteria codes in this bar 320 they will see a description for each criteria and they can click on individual criteria codes to link 321 to the pertinent section in the VCI. Additionally, a progress bar shows the number of criteria met 322 according to the strength of the evaluation and whether they are 'Benign' or 'Pathogenic' and also automatically calculates the pathogenicity each time an evaluation is saved or updated. At 323 324 any time a user can view an 'Evaluation Summary' that summarizes all their evaluated evidence. 325 If a criterion code is not evaluated then it would not be considered in the calculation of a 326 predicted classification. Once a biocurator is satisfied they have reviewed all pertinent evidence, 327 and evaluated all relevant criteria, they can save their classification as 'Provisional'. This 328 generates a PDF version of the 'Evaluation Summary' that can be distributed among the VCEP 329 membership domain experts to aid in their review process. Upon satisfactory completion of the

review process a final classification can be saved as 'Approved', at which point the 'EvaluationSummary' can now be viewed by all VCI users.

332

### 333 FDA Recognition and Data Dissemination

The VCI generates an output file of the final variant pathogenicity classification in an autogenerated format compatible with ClinVar submission specifications. This is intended to facilitate timely dissemination of variant classifications to the genomics community via ClinVar and is a requirement for ClinGen VCEPs. The ultimate goal is to support fully automated, APIbased ClinVar submission through the VCI once ClinVar provides support for API-based submission. Once submitted, a 'submission to ClinVar' (SCV) identifier is obtained and can be viewed in the VCI variant record.

The ClinGen variant curation process was recognized by the FDA in December 2018<sup>25</sup>, and is 341 followed by all ClinGen VCEPs. The evidence curation data and pathogenicity classifications 342 343 generated within the VCI by ClinGen VCEPs are therefore considered to be valid scientific 344 evidence that can be used to streamline the test development and validation processes. As such, 345 additional steps and requirements apply to the information specifically generated through the 346 ClinGen VCEP variant curation and classification process. Specifically, all the evidence that has 347 been curated and evaluated, along with provenance should be made publicly available and easily 348 accessible. With this in mind the VCI saves all evidence that is evaluated by its users. In 349 addition, upon final approval of a classification from a ClinGen VCEP, the VCI facilitates data 350 flow to the ClinGen Evidence Repository (ERepo), where the finalized classifications and 351 associated evidence evaluation is published. Importantly, the VCEP generated variant record in 352 the ERepo includes comments for specific codes enabling in-depth, and transparent data for peer review. (Figure 1). These publicly accessible displays of the final ClinGen VCEP variant
 classifications are accessed via the ERepo API at <u>https://erepo.clinicalgenome.org/evrepo/</u>.

- - -

356

357 *Current status and users* 

358

VCI currently has over 1,100 registered users, two-thirds of whom are members of ClinGen VCEPs (**Figure 6**). The VCI is publicly-accessible (with registration) for variant curation. When curating together as an affiliation, all members can view and edit all information added by anyone in that affiliation. This popular feature is currently used by 79 registered affiliations, most of which represent official ClinGen VCEPs but also include other affiliations of ClinGen members (e.g. institution-specific biocurator teams) and groups unrelated to ClinGen (e.g. clinical and research laboratories).

366

#### 367 Discussion:

368

Here we present the development of a genetic variant biocuration platform for health care providers, researchers and the medical genetics community to determine which gene variants are causal for a disease. The VCI supports the FDA-recognized ClinGen variant curation process and combines clinical, genetic, population, and functional evidence with expert review to classify variants into ACMG/AMP 2015 variant classification guideline categories<sup>1</sup>. Primary features of the VCI include the ability to 1) curate individually or in groups, 2) associate pertinent evidence with variant classifications, 3) allow users to assess evidence per variant curation disease/genespecific protocols, 4) enable users to save provisional records, 5) support an expert review
process of curated evidence, and 6) automatically publish classifications and underlying criteria
assessments to the ERepo

379

380 Future VCI improvements will focus on enhancing scale, workflow, throughput, and support 381 ongoing compliance with FDA recognition of the ClinGen Variant Curation Expert Panels 382 through the FDA Human Variant Database program. The current VCI v2.0 platform has over 383 6,300 variant classifications in different curation stages, and our modernized architecture is able 384 to scale to support over 1 million future classifications. We plan to enhance workflow usability 385 and curation efficiency by making the platform more proactive with: 1) task management 386 (supporting assigning of variant classification records to users) and action items (alerts to users), 2) support for bulk variant curation workflows, 3) automatically bring in additional variant 387 388 evidence data and monitor major data changes via a streaming service so curations can be 389 updated as needed, and 4) provide customized curation experiences based on VCEP 390 specifications. To ensure compliance with FDA requirements for the auditability of ClinGen 391 variant curation process, the VCI database maintains a complete audit trail of all saved curation 392 actions. We will further support FDA compliance with 1) additional traceability, 2) permanent 393 archiving, 3) regular knowledge updating through literature and database monitoring, and 4) 394 update alerts provided to curation teams.

395

The VCI provides needed software infrastructure and a comprehensive curation platform
necessary for supporting variant classification, a critical step in the use of genomics in medicine.
This global open source platform aids individual biocurators and teams of collaborating

biocurators in performing the complex task of variant curation in an efficient workflow to
enforce rigor and quality in variant classification ultimately contributing to scientific
advancement and informing health care management.

402

403 Acknowledgements:

404

All authors contributed to the project design. C.G.P., M.W.W., R.M., and H.A.C. drafted the initial version of the manuscript. All authors contributed to and approved the final version of the manuscript. We would like to thank all of the members of the Clinical Genome Resource consortium, especially the core members attending bimonthly VCI feedback meetings for their continual feedback.

410

```
411 Availability:
```

412

All code for the VCI including front-end, back-end, database schemas, analysis pipelines, and
user interfaces are freely available under MIT Open Source licenses via the GitHub repositories
(https://github.com/ClinGen/ and https://github.com/ClinGen/clincoded/).

416

## 417 **References**:

- 418 1. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a
- 419 joint consensus recommendation of the American College of Medical Genetics and
- 420 Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
- 421 2. Niehaus, A. et al. A survey assessing adoption of the ACMG-AMP guidelines for
- 422 interpreting sequence variants and identification of areas for continued improvement.

- 423 *Genetics in medicine: official journal of the American College of Medical Genetics* vol. 21
  424 1699–1701 (2019).
- 425 3. Rehm, H. L. *et al.* ClinGen--the Clinical Genome Resource. *N. Engl. J. Med.* 372, 2235–
  426 2242 (2015).
- 427 4. Amendola, L. M. et al. Performance of ACMG-AMP Variant-Interpretation Guidelines
- among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
- 429 Am. J. Hum. Genet. 98, 1067–1076 (2016).
- 430 5. Abou Tayoun, A. N. et al. Recommendations for interpreting the loss of function PVS1

431 ACMG/AMP variant criterion. *Hum. Mutat.* **39**, 1517–1524 (2018).

- 432 6. Biesecker, L. G., Harrison, S. M. & ClinGen Sequence Variant Interpretation Working
- 433 Group. The ACMG/AMP reputable source criteria for the interpretation of sequence
- 434 variants. *Genetics in medicine: official journal of the American College of Medical Genetics*
- 435 vol. 20 1687–1688 (2018).
- 436 7. Brnich, S. E. et al. Recommendations for application of the functional evidence PS3/BS3
- 437 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med.*

**438 12**, 3 (2019).

- 439 8. Luo, X. *et al.* ClinGen Myeloid Malignancy Variant Curation Expert Panel
- recommendations for germline RUNX1 variants. *Blood Advances* vol. 3 2962–2979 (2019).
- 441 9. Lee, K. *et al.* Specifications of the ACMG/AMP variant curation guidelines for the analysis
  442 of germline CDH1 sequence variants. *Hum. Mutat.* **39**, 1553–1568 (2018).
- 443 10. Oza, A. M. *et al.* Expert specification of the ACMG/AMP variant interpretation guidelines
  444 for genetic hearing loss. *Hum. Mutat.* 39, 1593–1613 (2018).
- 445 11. Ghosh, R. et al. Updated recommendation for the benign stand-alone ACMG/AMP

- 446 criterion. *Hum. Mutat.* **39**, 1525–1530 (2018).
- 447 12. Mester, J. L. *et al.* Gene-specific criteria for PTEN variant curation: Recommendations
  448 from the ClinGen PTEN Expert Panel. *Hum. Mutat.* **39**, 1581–1592 (2018).
- 13. Zastrow, D. B. *et al.* Unique aspects of sequence variant interpretation for inborn errors of
- 450 metabolism (IEM): The ClinGen IEM Working Group and the Phenylalanine Hydroxylase
- 451 Gene. *Human Mutation* vol. 39 1569–1580 (2018).
- 452 14. Gelb, B. D. *et al.* ClinGen's RASopathy Expert Panel consensus methods for variant
  453 interpretation. *Genetics in Medicine* vol. 20 1334–1345 (2018).
- 454 15. Kelly, M. A. *et al.* Adaptation and validation of the ACMG/AMP variant classification
- 455 framework for MYH7-associated inherited cardiomyopathies: recommendations by
- 456 ClinGen's Inherited Cardiomyopathy Expert Panel. *Genetics in Medicine* vol. 20 351–359
  457 (2018).
- Tavtigian, S. V. *et al.* Modeling the ACMG/AMP variant classification guidelines as a
  Bayesian classification framework. *Genet. Med.* 20, 1054–1060 (2018).
- 460 17. Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation and
  461 human phenotype. *Nucleic Acids Res.* 42, D980–5 (2014).
- 462 18. Shefchek, K. A. *et al.* The Monarch Initiative in 2019: an integrative data and analytic
- platform connecting phenotypes to genotypes across species. *Nucleic Acids Res.* 48, D704–
  D715 (2020).
- 465 19. Köhler, S. *et al.* Expansion of the Human Phenotype Ontology (HPO) knowledge base and
  466 resources. *Nucleic Acids Res.* 47, D1018–D1027 (2019).
- 467 20. Matched Annotation from NCBI and EMBL-EBI (MANE).
- 468 https://www.ncbi.nlm.nih.gov/refseq/MANE/.

469	21.	Esposito, D. et al. MaveDB: an open-source platform to distribute and interpret data from
470		multiplexed assays of variant effect. Genome Biol. 20, 223 (2019).
471	22.	Gelman, H. et al. Recommendations for the collection and use of multiplexed functional
472		data for clinical variant interpretation. Genome Med. 11, 85 (2019).
473	23.	Harrison, S. M., Biesecker, L. G. & Rehm, H. L. Overview of Specifications to the
474		ACMG/AMP Variant Interpretation Guidelines. Curr. Protoc. Hum. Genet. 103, e93
475		(2019).
476	24.	Rivera-Muñoz, E. A. et al. ClinGen Variant Curation Expert Panel experiences and
477		standardized processes for disease and gene-level specification of the ACMG/AMP
478		guidelines for sequence variant interpretation. Hum. Mutat. 39, 1614–1622 (2018).
479	25.	Office of the Commissioner. FDA takes new action to advance the development of reliable
480		and beneficial genetic tests that can improve patient care. https://www.fda.gov/news-
481		events/press-announcements/fda-takes-new-action-advance-development-reliable-and-
482		beneficial-genetic-tests-can-improve-patient (2018).
483	26.	Pawliczek, P. et al. ClinGen Allele Registry links information about genetic variants. Hum.
484		Mutat. <b>39</b> , 1690–1701 (2018).
485	27.	NCBI Resource Coordinators. Database resources of the National Center for Biotechnology
486		Information. Nucleic Acids Res. 46, D8–D13 (2018).
487	28.	McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
488	29.	Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic
489		Acids Res. 47, W636–W641 (2019).
490	30.	Xin, J. et al. High-performance web services for querying gene and variant annotation.
491		Genome Biol. 17, 91 (2016).

492	31.	Marcus, J. H. & Novembre, J. Visualizing the geography of genetic variants. Bioinformation	cs
493		<b>33</b> , 594–595 (2017).	

- 494 32. Braschi, B. *et al.* Genenames.org: the HGNC and VGNC resources in 2019. *Nucleic Acids*
- *Res.* 47, D786–D792 (2019).
- 496 33. Wu, C., Macleod, I. & Su, A. I. BioGPS and MyGene.info: organizing online, gene-centric
  497 information. *Nucleic Acids Res.* 41, D561–5 (2013).

# 

- 527
- 528
- 529 530
- 531
- 532
- 533

# 534 Figure and Figure Legends:

535

Figure 1: ClinGen FDA-Recognized Variant Curation Process and VCI. Overview of the ClinGen Variant Curation Process using the VCI, an FDA-recognized workflow. Biocurators select a variant, and evaluate evidence that falls into six categories. VCI viewers may view all evidence available for any variant using the VCI. The VCI supports users in making a final pathogenicity classification keeping with the ACMG/AMP guidelines. ClinGen expert panels then disseminate their variant classifications through two community resources: the Evidence Repository (ERepo) and ClinVar.





546 The VCI uses a data model centered on a classification (dark blue center box), with relationships

to other data models (white boxes). Each assertion is uniquely defined by the Variant, Disease

- and Mode of Inheritance models, and is owned by a user or affiliation. It has two core attributes
- a) status indicating its state in the current workflow cycle and b) selected classification (Figure
- 1). It uses different types of Evidence (see Evidence Collection in Figure 1) and applies an

Evidence Criteria to arrive at the selected classification. Each evidence type can use Articles as
supplementary evidence. As an interpretation progresses through review statuses (such as
review, approved, and published), snapshots of the full data at each review step are created. The
relationships between data models are represented here, with 1:1 (solid green lines), 1 to many
(N), or many to many (N to N) indicated.



569 External Resources Manager retrieves population, predictive, functional and other variant and gene-level data from external sources (Table 1) via APIs. In addition, the user can add in curated 570 571 evidence, evaluate against ACMG/AMP guidelines and save the classification for review and 572 approval. The approved classifications are then submitted to the ClinGen Evidence Repository. All data are saved in a database via microservices and can be accessed via queries. The Amazon 573 574 Cloud Services provide the microservices to store and retrieve data adopting a Serverless 575 Architecture utilizing the following components and services: Amplify, Cognito, API Gateway, Lambda, DynamoDB, S3, and the user-facing web interface is created using React Javascript 576 Library. 577



581

**Figure 4: The Basic Information View**. The VCI has six tab views that collate and display variant information from external and internal sources to biocurators. (**A**) The top title view is always viewable and shows the variant title, links to the variant in external resources, and key curation information for the record. (**B**) The criteria bar displays evaluated criteria and the calculated pathogenicity. (**C**) The basic information tab displays any curations available for the variant in the VCI and ClinVar, and transcript information from RefSeq and Ensembl.

<sup>580</sup> 

Variant ID Sources ClinVar Variation ID: <u>449490</u> ClinGen Allele Registry ID: <u>C</u> dbSNP ID: <u>rs141774369</u>	Link 이 전 UCS A6904317 전 Vari Ensi	s to External F GC [GRCh38/h ation Viewer [ embl Browser	Resources g38 년   GRCh37/hg19 <u>[</u> 3RCh38 년   GRCh37 년 GRCh38 년   GRCh37 년	My Interpretation Disease: nonsy (MON) Pathogenicity: Modified Pathogenicity: Provisional/App	ndromic genetic dea DO:0019497 (7) Likely pathogenic Igenicity: Not provid proved Status: Pub
/ariant Interpretatio	on Record				Disease 💼 🛛 Inher
Benign No criteria met	ø	Pathogenic Moderate:	Supporting:	Likely path	ed Pathogenicity
BA1 BS1 BS2 BS3 BS4	BP1 BP2 BP3 BP4 I	BP5 BP6 BF	7 PP1 PP2 PP3 P	P4 PP5 PM1 PM2	PM3 PM4 PM5
P32 P33 P34 PV31					
Basic Information Po	pulation Variant T	ype Exp	erimental Case/	Segregation Gene	e-centric
All interpretations for	this variant in the Va	ariant Curat	ion Interface (VCI)	0	
Clinical significance	Status C	ondition - Mo	de of inheritance		Curator/Affiliation
Likely pathogenic	PUBLISHED D	onsyndromic g	enetic deafness (MON	DO 0019497 (3)	Hearing Loss
	-	Autosomal rec	essive inheritance		
Overall ClinVar Intern	retation				See data in Clin
Boview status:	reviewed by expert pa		Lastava	luatode	500 Gata III Cilli
Clinical significance:	Likely pathogenic	lei	Number	of submission(s):	1 1
Interpretations Submitted to ClinVar (Germline SCVs only) ()					
Interpretations Sub					
Interpretations Sub Clinical significance	Review Status	Condition	(s)	Submitter -	Submission
Clinical significance (Last evaluated)	Review Status (Assertion Method)	Condition( (Mode of in	's) nheritance)	Submitter - Study name	Submission accession
Likely pathogenic (Jul 28, 2020)	Review Status (Assertion Method) reviewed by expert panel	Condition (Mode of in Nonsyndron and deafnes	is) nheritance) nic hearing loss ss (Autosomal	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert	Submission accession SCV001428435.
Clinical significance (Last evaluated) Likely pathogenic (Jul 28, 2020)	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1 [7]	Condition (Mode of in Nonsyndron and deafnes recessive in [MONDQ: M	s) nheritance) nic hearing loss ss (Autosomal heritance) 10NDO 0019497]	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C	Submission accession SCV001428435.
Clinical significance (Last evaluated) Likely pathogenic (Jul 28, 2020)	Review Status (Assertion Method) reviewed by expert panel ClinGen.HL.ACMG Specifications v1	Condition( (Mode of in Nonsyndron and deafnes recessive in [MONDO: N	s) nheritance) nic hearing loss ss (Autosomal heritance) IONDO 0019497]	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C	Submission accession SCV001428435.
Clinical significance (Last evaluated) Likely pathogenic (Jul 28, 2020)	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1	Condition (Mode of in Nonsyndron and deafnes recessive in [MONDQ: M	s) nheritance) nic hearing loss ss (Autosomal heritance) IONDO 0019497]	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C	Submission accession SCV001428435
Clinical significance (Last evaluated) Likely pathogenic (Jul 28, 2020) RefSeq Transcripts	Review Status (Assertion Method) reviewed by expert panel ClinGen HLACMG Specifications v1 <sup>C*</sup>	Condition( (Mode of in Nonsyndrom and deafnes recessive in (MONDQ: N	s) nheritance) nic hearing loss ss (Autosomal heritance) 10NDO 0019497] Protein Change	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C	Submission accession SCV001428435.
Interpretations Subility         Clinical significance (Last evaluated)         Likely pathogenic (Jul 28, 2020)         RefSeq Transcripts         Nucleotide Change         NM 004004.6:c.110T>C	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1 C	Condition (Mode of in Nonsyndron and deafnes recessive in (MONDC: M Exon	s) nheritance) nic hearing loss ss (Autosomal heritance) IONDO 0019497] Protein Change NP 003995.2:p.Val37	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C Molecular C Ala missense val	Submission accession SCV001428435.
Interpretations Subility         Clinical significance (Last evaluated)         Likely pathogenic (Jul 28, 2020)         RefSeq Transcripts         Nucleotide Change         NM_004004.6:c.110T>C         XM 011525040 2:c.110T	Review Status (Assertion Method) reviewed by expert panel ClinGen HLACMG Specifications v1	Condition (Mode of in Nonsyndrom and deafnes recessive in (MONDQ: M Exon 2/2	s) nheritance) nic hearing loss ss (Autosomal heritance) 10NDO 0019497] Protein Change NP_003995.2:p.Val37	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C Molecular C Ala missense_var	Submission accession SCV001428435.
Interpretations Subility         Clinical significance (Last evaluated)         Likely pathogenic (Jul 28, 2020)         RefSeq Transcripts         Nucleotide Change         NM_004004.6:c.110T>C         XM_011535049.2:c.110T	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1 C (GJB2) (MANE Select) C >C (GJB2)	Condition (Mode of in Nonsyndron and deafnes recessive in (MONDQ: M Exon 2/2 2/2	s) nheritance) nic hearing loss ss (Autosomal heritance) IONDO 0019497] Protein Change NP_003995.2:p.Val37 XP_011533351.1:p.Val	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C Molecular C Ala missense_val 37Ala missense_val	Submission accession SCV001428435.
Interpretations Subility         Clinical significance (Last evaluated)         Likely pathogenic (Jul 28, 2020)         RefSeq Transcripts         Nucleotide Change         NM_004004.6:c.110T>C         XM_011535049.2:c.110T         Ensembl Transcripts	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1 (GJB2) (GJB2) (MANE Select) C >C (GJB2)	Condition (Mode of in Nonsyndron and deafnes recessive in (MONDQ: M Exon 2/2 2/2	s) nheritance) nic hearing loss ss (Autosomal heritance) 10NDO 0019497] Protein Change NP_003995.2:p.Val37 XP_011533351.1:p.Val	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C Molecular C Ala missense_van 37Ala missense_van	Submission accession SCV001428435. onsequence riant
Interpretations Subi Clinical significance (Last evaluated) Likely pathogenic (Jul 28, 2020) RefSeq Transcripts Nucleotide Change NM_004004.6:c.110T>C XM_011535049.2:c.110T Ensembl Transcripts Nucleotide Change	Review Status (Assertion Method) reviewed by expert panel ClinGen HL ACMG Specifications v1 C (GJB2) MANE Select C >C (GJB2) VCP	Condition (Mode of in Nonsyndrom and deafnes recessive in (MONDC: M Exon 2/2 2/2 2/2 Exon	s) hheritance) nic hearing loss is (Autosomal heritance) IONDO 0019497] Protein Change NP_003995.2:p.Val37 XP_011533351.1:p.Val Protein Change	Submitter - Study name ClinGen Hearing Loss Variant Curation Expert Panel C Molecular C Ala missense_var 37Ala missense_var	Submission accession SCV001428435. onsequence riant riant

Figure 5: Case and Segregation Evidence Capture. The structured data capture for the
case/segregation view in the VCI, including the (A) top title view (B) Evidence sources are
captured and structured so that users can quickly see all sources and the summed individual
counts from the pooled evidence for specific ACMG/AMP criteria (shown here is PM3).



Figure 6: VCI Platform growth over time. (A) Number of curated variant classifications
performed in the VCI over time. (B) The number of biocurators and biocurator affiliations
accumulated over time are noted at the top of each bar.



601

Α





	<ul><li>Variant ID</li><li>HGVS terms</li></ul>	ClinGen Allele Registry <sup>26</sup>
Basic Information	<ul> <li>ClinVar Variation ID</li> <li>ClinVar Overall interpretation</li> <li>ClinVar Submitted interpretations</li> <li>ClinVar Primary transcript</li> <li>RefSeq transcripts</li> <li>dbSNP variant ID</li> <li>Entrez Gene ID</li> </ul>	NCBI E-utilities <sup>27</sup>
	<ul> <li>RefSeq transcripts</li> <li>Ensembl transcripts</li> <li>Molecular consequences</li> </ul>	Ensembl VEP <sup>28</sup>
	• Monarch Disease Ontology (Mondo) human disease term(s)	Ontology Lookup Service <sup>29</sup>
	• Phenotypic abnormality term(s)	Human Phenotype Ontology (HPO) <sup>19</sup>
	<ul> <li>Allele frequencies         <ul> <li>gnomAD</li> <li>ExAC</li> <li>Exome Sequencing Project</li> </ul> </li> </ul>	MyVariant.info <sup>30</sup>
Population	<ul> <li>Allele frequencies         <ul> <li>PAGE Study</li> </ul> </li> </ul>	GGV Browser <sup>31</sup>
	Allele frequencies         0 1000 Genomes	Ensembl VEP <sup>28</sup>
Variant Type	<ul> <li>In silico predictor scores         <ul> <li>REVEL</li> <li>SIFT</li> <li>PolyPhen2</li> <li>LRT</li> <li>MutationTaster</li> <li>MutationAssessor</li> <li>FATHMM</li> <li>PROVEAN</li> <li>MetaSVM</li> <li>MetaLR</li> <li>CADD</li> <li>FATHMM-MKL</li> <li>fitCons</li> </ul> </li> </ul>	MyVariant.info <sup>30</sup>

	<ul> <li>phyloP100way</li> <li>phyloP30way</li> <li>phastCons100way</li> <li>phastCons30way</li> <li>GERP++</li> <li>SiPhy</li> </ul>	
Experimental	• Experimental functional data	ClinGen Functional Data Repository (FDRepo)
	• Gene symbol	HGNC <sup>32</sup>
Gene-Centric	<ul> <li>ExAC constraint scores</li> <li>UniProt protein ID</li> <li>GeneCards gene</li> </ul>	MyGene.info <sup>33</sup>